Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novavax ( (NVAX) ) has issued an announcement.
On August 27, 2025, Novavax announced that the FDA approved its Nuvaxovid 2025-2026 formula, a protein-based COVID-19 vaccine, for adults 65 and older and individuals 12-64 with underlying conditions. The approval includes extending the vaccine’s shelf life to six months and requires postmarketing studies to assess safety and post-vaccination syndrome. This approval positions Novavax as the only provider of a non-mRNA COVID-19 vaccine in the U.S. for the 2025-2026 season, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (NVAX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
Spark’s Take on NVAX Stock
According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.
Novavax’s overall stock score reflects financial instability and operational challenges, despite positive technical indicators and valuation. The earnings call and corporate events provide optimism for future growth, but immediate financial risks remain significant.
To see Spark’s full report on NVAX stock, click here.
More about Novavax
Novavax, Inc. is a biotechnology company specializing in vaccine development, utilizing its proprietary protein-based nanoparticle technology and Matrix-M adjuvant. The company focuses on addressing global health challenges through innovation in infectious diseases and aims to expand its technology platform through partnerships and collaborations.
Average Trading Volume: 6,570,665
Technical Sentiment Signal: Sell
Current Market Cap: $1.22B
For an in-depth examination of NVAX stock, go to TipRanks’ Overview page.